Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: A pilot study

Diabetes Care

Volumn 33, Issue 9, 2010, Pages 2074-2076

  Sathananthan, Airani ^a   Dalla Man, Chiara ^b   Micheletto, Francesco ^b   Zinsmeister, Alan R ^a   Camilleri, Michael ^a   Giesler, Paula D ^a   Laugen, Jeanette M ^a   Toffolo, Gianna ^b   Rizza, Robert A ^a   Cobelli, Claudio ^b   Vella, Adrian ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; GENETIC MODEL; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN RELEASE; NORMAL HUMAN; PANCREAS ISLET BETA CELL; PILOT STUDY; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

C-PEPTIDE; GENOTYPE; GLUCAGON-LIKE PEPTIDE 1; HETEROZYGOTE; HUMANS; INSULIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, GLUCAGON;

EID: 78650890818     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0200     Document Type: Article

References (10)

1. Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 2005;130:1-6 (Pubitemid 40966015)
2. Dalla Man C, Micheletto F, Sathananthan A, Rizza RA, Vella A, Cobelli C. A model of GLP-1 action on insulin secretion in non-diabetic subjects. Am J Physiol Endocrinol Metab 2010;298:E1115-1121
3. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001;50:150-158 (Pubitemid 32047994)
4. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-818 (Pubitemid 20343989)
5. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 2003;114:153-158 (Pubitemid 36773880)
6. Doyle ME, Greig NH, Holloway HW, Betkey JA, Bernier M, Egan JM. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. Endocrinology 2001;142:4462-4468 (Pubitemid 32907077)
7. Campioni M, Toffolo G, Shuster LT, Service FJ, Rizza RA, Cobelli C. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 2007;292:E54-E60 (Pubitemid 46052925)
8. Dalla Man C, Bock G, Giesler PD, Serra DB, Ligueros Saylan M, Foley JE, Camilleri M, Toffolo G, Cobelli C, Rizza RA, Vella A. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care 2009;32:14-18
9. Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004;36:830-836 (Pubitemid 40115906)
10. Stolerman ES, Florez JC. Genomics of type 2 diabetes mellitus: implications for the clinician. Nat Rev Endocrinol 2009;5:429-436